Clinical information on the analysed patients with UC
| No | Gender | Age | Mayo Score (endoscopic 0–3) | Histological assessment | Medication | Relapses/year (disease onset)* | PSC** |
|---|---|---|---|---|---|---|---|
| 1 | M | 47 | 0 | A, L | 5-ASA | <1 | x |
| 2 | M | 24 | 0 | NAD | 5-ASA+azathioprine | <1 | x |
| 3 | M | 26 | 0 | A, L, E | 5-ASA+azathioprine | <1 | |
| 4 | M | 57 | 0 | NAD | 5-ASA | <1 | |
| 5 | M | 29 | 0 | A | 5-ASA | <1 | |
| 6 | M | 53 | 0 | A | 5-ASA+TNFa inhibitors† | <1 | |
| 7 | F | 58 | 0 | NAD | 5-ASA | <1 | |
| 8 | M | 32 | 0 | NAD | 5-ASA+azathioprine | ≥1 | |
| 9‡ | M | 24 | 0 | A | 5-ASA+azathioprine | <1 | x |
| 10 | M | 27 | 0 | A | 5-ASA | (Onset 2011) | |
| 11 | F | 22 | 0 | L, C | 5-ASA+steroids | (Onset 2011) | |
| 12 | M | 74 | 0 | A | 5-ASA | <1 | |
| 13 | F | 55 | 0 | A | 5-ASA | <1 | |
| 14 | M | 34 | 0 | NAD | None | <1 | |
| 15 | M | 27 | 0 | NAD | 5-ASA | ≥1 | |
| 16 | M | 72 | 0 | NAD | 5-ASA | <1 | |
| 17 | M | 38 | 0 | NAD | 5-ASA | (Onset 2011) | |
| 18 | F | 65 | 1 | A, L, E, P, N, C, CA | 5-ASA | <1 | |
| 19 | F | 37 | 1 | L, E, C, CA | 5-ASA | <1 | |
| 20 | M | 52 | 2 | L, E, P, CA, U | 5-ASA | (Onset 2008) | |
| 21 | M | 28 | 2 | A, L, E, C, CA | 5-ASA | (Onset 2009) | |
| 22 | F | 31 | 2 | A, L, E, C | 5-ASA | ≥1 | |
| 23 | M | 36 | 3 | A, L, N, D | 5-ASA+azathioprine | ≥1 | |
| 24 | M | 62 | 1 | A, L, C | 5-ASA+steroids | ≥1 | |
| 25 | M | 26 | 2 | A, L, E, P, C, CA | 5-ASA+azathioprine | ≥1 | |
| 26 | M | 45 | 2 | A, L, C | 5-ASA+azathioprine | ≥1 | |
| 27 | M | 18 | 2 | A, L, E, P, C, CA, D, U | 5-ASA+azathioprine | ≥1 | |
| 28 | F | 21 | 1 | A, L, E, P | 5-ASA+TNFα inhibitors | ≥1 |
*For patients with recent disease onset, the number of relapses cannot be given. Instead year of debut is stated in parentheses.
**PSC, primary sclerosing cholangitis. x, means present.
†Medication with TNFα inhibitor for rheumatoid arthritis.
‡This patient had inflammation in more proximal part.
5-ASA, 5-aminosalicylic acid; A, alterations in crypt architecture; C, cryptitis; CA, crypt abscesses; D, denuded epithelium; E, eosinophils; F, female; L, lymphocytes; M, male; N, neutrophils; NAD, nothing abnormal detected; P, plasma cells; PSC, primary sclerosing cholangitis; TNF, tumour necrosis factor; U, ulceration; UC, ulcerative colitis.